Jazz Pharmaceuticals plc (JAZZ)
| Market Cap | 6.68B |
| Revenue (ttm) | 3.91B |
| Net Income (ttm) | 394.92M |
| Shares Out | 61.75M |
| EPS (ttm) | 5.93 |
| PE Ratio | 18.17 |
| Forward PE | 5.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 285,509 |
| Open | 108.37 |
| Previous Close | 108.52 |
| Day's Range | 106.85 - 108.84 |
| 52-Week Range | 99.06 - 137.39 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 173.14 (+60.14%) |
| Earnings Date | Nov 6, 2024 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is $173.14, which is an increase of 60.14% from the latest price.
News
Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market
Jazz Pharmaceuticals (JAZZ, Financial), a leading player in the narcolepsy market, is expanding its reach into other markets such as the non-small cell lung cancer (NSCLC) market by preparing a new bi...
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free survival (m...
Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
New and updated data from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for first-line treatment of HER2-positive...
Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024
Data from eight abstracts to be presented, including results of the BECOME (BEhavior, COgnition and More with Epidyolex®) Caregiver Survey on the real-world outcomes of Epidyolex® (cannabidiol) treatm...
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
DUBLIN , Sept. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 3.125% exchangeable se...
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
DUBLIN , Sept. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), int...
Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies
DUBLIN , Aug. 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 open-label, single-arm trial in Japan evaluating the safety and efficac...
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
DUBLIN , Aug. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Wells Fargo Healthcare Co...
Jazz Pharmaceuticals plc (JAZZ) Q2 2024 Earnings Call Transcript
Jazz Pharmaceuticals plc. (NASDAQ:JAZZ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Andrea Flynn - Vice President and Head-Investor Relations Bruce Cozadd - Chairma...
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance
– 15% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenues grew 10% year-over-year –– Zanidatamab granted Priority Review by U.S. FDA f...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting
Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today ann...
Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
DUBLIN , July 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that it has completed a repricing of the approximately $2.7 billion outstanding ...
Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
DUBLIN , July 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 second quarter financial results on Wednesday, July 31, 2024, after the clos...
Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer
Ms. Pearce brings over 30 years of commercial experience and track record of success across global markets DUBLIN , July 9, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced...
Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jazz Pharmaceuticals plc's suvecaltamide failed in a phase 2b trial for essential tremor, but this is a minor setback for the company and one that should have been expected. The oxybate franchise is p...
Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
Thursday, Jazz Pharmaceuticals plc JAZZ released topline results from the Phase 2b trial evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-de...
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study
Jazz Pharmaceuticals said on Thursday its experimental drug to treat a neurological condition that causes involuntary and rhythmic shaking failed to meet the main goal in a mid-stage study.
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
DUBLIN , June 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and safety of suv...
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ t...
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
Thirteen abstracts, including five late-breaking abstracts, underscore Jazz's ongoing commitment to advancing the understanding and treatment of serious sleep disorders Oral presentation of XYLO study...
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
DUBLIN , May 29, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcar...
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Target Action (PDUFA) Date set for November 29, 2024 If approved, zanidatamab will be the first HER2-targeted treatment specifically indicated for patients with HER2+ locally advanced or metastatic bi...
Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism
DUBLIN , May 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in ...
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
DUBLIN , May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care Conference on Wedne...
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
– 12% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenues grew 13% year-over-year –– Submitted zanidatamab BLA for 2L BTC; expect to l...